קרניטין תמיסה % 30 ישראל - עברית - Ministry of Health

קרניטין תמיסה % 30

abic marketing ltd, israel - levocarnitine - תמיסה - levocarnitine 30 % - levocarnitine - levocarnitine - systemic and myopathic carnitine deficiency.

בטנזול טבליות ישראל - עברית - Ministry of Health

בטנזול טבליות

devries & co. ltd - betamethasone - טבליה - betamethasone 0.5 mg - betamethasone - betamethasone - diseases responsive to oral glucocorticosteroid therapy.

לורמיקס 200 מג ישראל - עברית - Ministry of Health

לורמיקס 200 מג

megapharm ltd - rifaximine - טבליות מצופות פילם - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria

לבטיראצטם אלטן 100 מגמל ישראל - עברית - Ministry of Health

לבטיראצטם אלטן 100 מגמל

propharm ltd - levetiracetam - תרכיז להכנת תמיסה לאינפוזיה - levetiracetam 100 mg / 1 ml - levetiracetam

DISPOSABLE LABWARE IN PLASTIC ישראל - עברית - Ministry of Health

disposable labware in plastic

בר-נאור בע"מ - אחר - מוצרים מתכלים למעבדות

טסיגנה 200 מג ישראל - עברית - Ministry of Health

טסיגנה 200 מג

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

טסיגנה 150 מג ישראל - עברית - Ministry of Health

טסיגנה 150 מג

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

בינוקריט 1000 יחבל 0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל ישראל - עברית - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 30000 יחבל 0.75 מל ישראל - עברית - Ministry of Health

בינוקריט 30000 יחבל 0.75 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob